Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 24, 2024
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2024-01-23$63.69/sh−7,378$469,905→ 58,458 total
Footnotes (1)
- [F1]This is a scheduled sale from an established 10b5-1 plan.